Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.

Abstract: Provided are a touch panel, a method of manufacturing the same, and a touch panel integrated organic light emitting display device. The touch panel includes a substrate, a plurality of connection electrodes, an over-coating layer, a first line electrode, a second line electrode, a plurality of first segment electrodes, and a plurality of second segment electrodes. The plurality of connection electrodes is disposed on the substrate to be separated from each other. The over-coating layer includes a plurality of contact holes exposing a part of each connection electrode. The second line electrode is connected with the connection electrode through the contact hole of the over-coating layer without disconnection.

Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.

Abstract: A refrigerator includes a mid-frame positioned on a front surface of the main body wall and a heater configured to heat the mid-frame and provided at the mid-frame. The mid-frame includes a front frame provided to cover at least a part of a front surface of the at least one inner box configured to form the main body wall, and an extension frame formed to extend rearward from the front frame and including an edge portion in which an end portion of the extension frame has a thickness greater than that of an adjacent extension frame.

Abstract: Disclosed is a tire-reinforcing steel cord for a radial tire. The tire-reinforcing steel cord has a double layer structure including a first-layer core and a second-layer core provided on the surface of the first-layer core. The first-layer core has an elliptical or rectangular cross section. The tire-reinforcing steel cord can improve processability, fatigue characteristics, and rolling resistance performance of a tire, resulting in improved fuel efficiency. A radial tire using the tire-reinforcing steel cord is also disclosed.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R3, and X1 to X6 are the same as defined in Claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in Claim 1.

Abstract: A hybrid cord for a tire, a method of manufacturing the same, and a high-performance environment-friendly radial tire including the same are disclosed herein. The hybrid cord includes a high-modulus fiber ply and a low-modulus fiber ply. The hybrid cord has a stress-strain curve including an initial modulus section, an intermediate modulus section and a final modulus section. The initial modulus of the initial modulus section is higher than the intermediate modulus of the intermediate modulus section, and the final modulus of the final modulus section is higher than the intermediate modulus.

Abstract: The present invention relates to epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-a, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.

Abstract: An organic light emitting display device is disclosed. The organic light emitting display device includes: an organic light emitting display panel defined into a display area for displaying an image and a non-display area surrounding the display area; a chip-on-film loaded with a driver IC chip, which is configured to drive the organic light emitting display panel, and attached to a pad portion which is formed on the non-display area of the organic light emitting display panel; and a printed circuit board configured to apply signals to the driver IC chip and attached to one edge of the chip-on-film, wherein the organic light emitting display panel includes a dummy pad portion which is formed on the non-display area in the same configuration as the pad portion and in opposition to the pad portion.

Abstract: Disclosed is a tire-reinforcing steel cord for a radial tire. The tire-reinforcing steel cord has a double layer structure including a first-layer core and a second-layer core provided on the surface of the first-layer core. The first-layer core has an elliptical or rectangular cross section. The tire-reinforcing steel cord can improve processability, fatigue characteristics, and rolling resistance performance of a tire, resulting in improved fuel efficiency. A radial tire using the tire-reinforcing steel cord is also disclosed.

Abstract: A method of fabricating a thin film transistor substrate includes: forming a polymer layer on a glass substrate; forming a passivation layer on the polymer layer; forming a thin film transistor array on the passivation layer; and separating the glass substrate from the polymer layer by irradiating a laser from a rear surface of the glass substrate.

Abstract: An organic light emitting display device is disclosed. The organic light emitting display device includes: an organic light emitting display panel defined into a display area for displaying an image and a non-display area surrounding the display area; a chip-on-film loaded with a driver IC chip, which is configured to drive the organic light emitting display panel, and attached to a pad portion which is formed on the non-display area of the organic light emitting display panel; and a printed circuit board configured to apply signals to the driver IC chip and attached to one edge of the chip-on-film, wherein the organic light emitting display panel includes a dummy pad portion which is formed on the non-display area in the same configuration as the pad portion and in opposition to the pad portion.

Abstract: A method of fabricating a thin film transistor substrate includes: forming a polymer layer on a glass substrate; forming a passivation layer on the polymer layer; forming a thin film transistor array on the passivation layer; and separating the glass substrate from the polymer layer by irradiating a laser from a rear surface of the glass substrate.

Abstract: Disclosed herein are pyridine derivatives, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, pharmaceutical compositions comprising the same, and methods of modulating the level or activity of HIF in a subject, inhibiting hydroxylation of HIF ? in a subject, modulating expression of HIF-regulated genes in a subject, treating an HIF-related disorder in a subject, increasing levels of endogenous EPO in a subject, or treating a disorder in a subject, using the disclosed compounds.

Abstract: A compound of formula 1 efficiently inhibits several protein kinases including glycogen synthase kinase 3 (GSK), aurora kinase, extracellular signal-regulated kinase (ERK), protein kinase B (AKT), and the likes, to control signal transductions involved in variable disorders such as diabetes, obesity, dementia, cancer, and inflammation.

Abstract: The present invention relates to a method for fabricating a conductive particle, the method comprising steps of: (a) preparing a particle based on a macromolecular resin; (b) forming a layer of a nano powder on a surface of the particle; and (c) subjecting the layer of the nano powder to an electroless plating. In accordance with the present invention, a nano powder is bonded on a particle based on a macromolecular resin and an electroless conductive layer is plated such that a pretreatment process of a plating process for forming a conductive particle is omitted and the plating process is simplified from twice to once, thereby reducing a toxic substance generated in a conventional process to improve a stability of the process and reduce a manufacturing cost.

Abstract: A process for stereoselective preparation of (E)-enolthioether derivatives comprising the steps of;(a) protecting free secondary hydroxy group of L-threonine with trialkylsilyl group; (b) the protected L-threonine derivatives (I) being degraded by ninhydrin to prepare (2R)-2-(trialkylsilyloxy)propanal (II); and (c) carting out the Honor-Wordsworth-Emons (HWE) reaction of the resultant compound (II) with stabilized phosphonate ylide, phosphonium ylide or phosphine oxide ylide which was obtained by treating the organic phosphine compound (III) with strong base to provide (E)-enolthioether derivatives (IV) is provided.The present invention has advantages in comparison with the prior art in that the costs required for the process can be lowered because L-threonine, an .alpha.-amino acid of low in price is used as a starting material and the process is simple; and the desired (E)-enolthioether derivatives can be prepared with high stereoselectivity.